MDT vs. BMY

In the year-to-date period, MDT achieves a 6.19% return, which is significantly higher than BMY's -13.45% return. Over the past 10 years, MDT has outperformed BMY with an annualized return of 3.53%, while BMY has yielded a comparatively lower 0.23% annualized return.

Search for stocks, ETFs, and funds for a quick comparison or use the comparison tool for more options.

This table presents a comparison of risk-adjusted performance metrics for Medtronic plc (MDT) and Bristol-Myers Squibb Company (BMY). Risk-adjusted metrics are performance indicators that assess an investment's returns in relation to its risk, enabling a more accurate comparison of different investment options.

The current MDT Sharpe Ratio is 0.33, which is higher than the BMY Sharpe Ratio of 0.08. The chart below compares the historical Sharpe Ratios of MDT and BMY, offering insights into how both investments have performed under varying market conditions. These values are calculated using daily returns over the previous 12 months.

MDT's dividend yield for the trailing twelve months is around 3.33%, less than BMY's 5.09% yield.

The maximum MDT drawdown since its inception was -57.63%, smaller than the maximum BMY drawdown of -70.62%. Use the drawdown chart below to compare losses from any high point for MDT and BMY. For additional features, visit the drawdowns tool.

Medtronic plc (MDT) and Bristol-Myers Squibb Company (BMY) have volatilities of 9.60% and 9.92%, respectively, indicating that both stocks experience similar levels of price fluctuations. This suggests that the risk associated with both stocks, as measured by volatility, is nearly the same. The chart below showcases a comparison of their rolling one-month volatility.

This section allows you to compare key financial metrics between Medtronic plc and Bristol-Myers Squibb Company. You can select fields from income statements, balance sheets, and cash flow statements to easily visualize and compare the financial health of both companies.